Hormone Therapy for Prostate Cancer Frederick MD

Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found. The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

Mohammed M Mohiuddin
(301) 694-8080
801 Toll House Ave
Frederick, MD
Specialty
Urology

Data Provided by:
Robert David Crouch
(301) 663-4774
900 Toll House Ave
Frederick, MD
Specialty
Urology

Data Provided by:
Robert David Crouch, MD
(301) 663-4774
900 Toll House Ave
Frederick, MD
Specialties
Urology, Surgery Critical Care-Surgery
Gender
Male
Education
Medical School: Med Univ Of Sc Coll Of Med, Charleston Sc 29425
Graduation Year: 1948
Hospital
Hospital: Frederick Mem Hosp, Frederick, Md

Data Provided by:
Mark Xavier Coyne, MD
(301) 695-6466
186 Thomas Johnson Dr Ste 104
Frederick, MD
Specialties
Urology
Gender
Male
Education
Medical School: Univ Auto De Guadalajara, Fac De Med, Guadalajara, Jalisco, Mexico
Graduation Year: 1977
Hospital
Hospital: Frederick Mem Hosp, Frederick, Md

Data Provided by:
Cynthia Joy Moorman, MD
(301) 662-4868
77 Thomas Johnson Dr Ste K
Frederick, MD
Specialties
Urology
Gender
Female
Education
Medical School: Univ Of Mi Med Sch, Ann Arbor Mi 48109
Graduation Year: 1987

Data Provided by:
Asghar Farsaii, MD
(301) 428-3040
610 Solarex Ct
Frederick, MD
Specialties
Urology
Gender
Male
Education
Medical School: Tabriz Univ, Fac Of Med, (Univ Of Azarabadegan) Tabriz, Iran
Graduation Year: 1968

Data Provided by:
Mohammed M Mohiuddin, MD
(301) 694-8080
801 Toll House Ave
Frederick, MD
Specialties
Urology
Gender
Male
Education
Medical School: Osmania Med Coll, Univ Hlth Sci, Vijayawada, Hyderabad, Ap, India
Graduation Year: 1969

Data Provided by:
Robert Craig Myers, MD
(626) 918-1881
5608 Honeysuckle Ct
Frederick, MD
Specialties
Urology
Gender
Male
Education
Medical School: Loma Linda Univ Sch Of Med, Loma Linda Ca 92350
Graduation Year: 1983

Data Provided by:
Bert Edward Williams
(301) 694-0414
97 Thomas Johnson Drive
Frederick, MD
Specialty
Urology

Data Provided by:
Mark Xavier Coyne
(301) 695-6466
186 Thomas Johnson Dr
Frederick, MD
Specialty
Urology

Data Provided by:
Data Provided by:

Hormone Therapy for Prostate Cancer

Provided By:

TUESDAY, Sept. 22 (HealthDay News) -- Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found.

The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

The study findings were scheduled to be presented Tuesday at the European Cancer Organization meeting in Berlin.

In a news release from the European Cancer Organization, the researchers described the types of hormone therapy used: removal of the testicles to eliminate the main source of testosterone production; injections of gonadotropin-releasing hormone agonists to reduce testosterone production by the testicles; and anti-androgen pills that block testosterone from attaching to prostate cells. Most of the patients received one treatment, but 38 percent were given two types of drugs, the study authors noted.

The men were followed for an average of three years and monitored for ischemic heart disease, heart attacks, arrhythmia, and heart failure.

"We found that prostate cancer patients treated with hormone therapy had an elevated risk of developing all of the individual types of heart problems and that they were more likely than normal to die from those causes," study lead author Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London, England, said in the news release.

Specifically, hormone therapy was associated with a 24 percent increased risk of heart attack, a 19 percent increased risk of arrhythmia, a 31 percent increased risk of ischemic heart disease, and a 26 percent increased risk of heart failure, the researchers found. The increased risk of heart disease began a few months after the men began hormone therapy.

The study also found that hormone therapy was associated with a 28 percent increased risk of fatal heart attack, a 21 percent increased risk of dying from heart disease, a 26 percent increased risk of death from heart failure, and a 5 percent increased risk of fatal arrhythmia.

"In a more detailed analysis by type of hormone therapy, the lowest increase in risk for ischemic heart disease, heart attack and heart failure was seen in the group taking anti-androgen therapy, and we saw no increase in risk of death from heart disease in this group. Patients on gonadotropin-releasing hormone agonist therapy had the highest risk of these problems," Van Hemelrijck said.

The findings suggest that physicians should consider heart-related side effects when prescribing hormone therapy for prostate cancer patients and may want to refer patients to a cardiologist before the start of hormone therapy, the researchers stated.

More information

The American Urological Association Foundation has more about hormone therapy for prostate cancer.

SOURCE: European Cancer Organization, news release, Sept. 22, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com